Purple Biotech Partners with Mount Sinai for Antibody Platform
Ticker: PPBT · Form: 6-K · Filed: Feb 3, 2025 · CIK: 1614744
Sentiment: neutral
Topics: collaboration, biotech, research
TL;DR
Purple Biotech teams up with Mount Sinai for new antibody tech - big potential!
AI Summary
On February 3, 2025, Purple Biotech Ltd. announced a research collaboration with the Icahn School of Medicine at Mount Sinai to advance their CAPTN-3 tri-specific antibody platform. This collaboration aims to explore the potential of this platform in treating various diseases.
Why It Matters
This collaboration could accelerate the development of novel therapies by leveraging the expertise of both Purple Biotech and Mount Sinai, potentially leading to new treatment options for patients.
Risk Assessment
Risk Level: medium — Biotech collaborations carry inherent risks related to research outcomes, regulatory approvals, and market adoption.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- Icahn School of Medicine at Mount Sinai (company) — Collaboration Partner
- CAPTN-3 (product) — Tri-Specific Antibody Platform
- February 3, 2025 (date) — Announcement Date
FAQ
What is the primary goal of the collaboration between Purple Biotech and the Icahn School of Medicine at Mount Sinai?
The primary goal is to advance Purple Biotech's CAPTN-3 tri-specific antibody platform.
What specific technology is Purple Biotech focusing on with this collaboration?
Purple Biotech is focusing on its CAPTN-3 tri-specific antibody platform.
When was the press release announcing this collaboration issued?
The press release was issued on February 3, 2025.
What type of issuer is Purple Biotech Ltd. according to this filing?
Purple Biotech Ltd. is a foreign private issuer.
What is Purple Biotech's SIC code?
Purple Biotech's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2025-02-03 07:04:46
Filing Documents
- ea0229548-6k_purplebio.htm (6-K) — 14KB
- ea022954801ex99-1_purplebio.htm (EX-99.1) — 16KB
- 0001213900-25-009090.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. February 3, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2